1
EXHIBIT 4.2
DIADEXUS, INC.
INVESTORS' RIGHTS AGREEMENT
April 6, 2000
2
TABLE OF CONTENTS
1. REGISTRATION RIGHTS 1
1.1 Definitions 1
1.2 Request for Registration 2
1.3 Company Registration 4
1.4 Form S-3 Registration 4
1.5 Obligations of the Company 5
1.6 Furnish Information 6
1.7 Expenses of Registration 7
1.8 Underwriting Requirements 7
1.9 Delay of Registration 8
1.10 Indemnification 8
1.11 Reports Under Securities Exchange Act of 1934 10
1.12 Assignment of Registration Rights 11
1.13 Limitations on Subsequent Registration Rights 11
1.14 Market-Standoff Agreement 11
1.15 Termination of Registration Rights 12
2. COVENANTS OF THE COMPANY 12
2.1 Delivery of Financial Statements 12
2.2 Inspection 13
2.3 Reservation of Common Stock 13
2.4 Proprietary Information and Inventions Agreement 13
2.5 Right of First Offer 13
2.6 Company Right of First Offer 15
2.7 Termination of Covenants 15
3. MISCELLANEOUS 16
3.1 Successors and Assigns 16
3.2 Amendments and Waivers 16
3.3 Notices 16
3.4 Severability 16
3.5 Governing Law 17
3.6 Counterparts 17
3.7 Titles and Subtitles 17
3.8 Aggregation of Stock 17
3
DIADEXUS, INC.
INVESTORS' RIGHTS AGREEMENT
This Investors' Rights Agreement (the "Agreement") is made as of the 6th
day of April, 2000, by and among diaDexus, Inc., a Delaware corporation (the
"Company"), the investors listed on Exhibit A hereto, each of which is herein
referred to as an "Investor," and SmithKline ▇▇▇▇▇▇▇ Corporation and Incyte
Pharmaceuticals, Inc., each of whom is herein referred to as a "Founder".
RECITALS
The Company and the Investors have entered into a Series C Preferred
Stock Purchase Agreement (the "Purchase Agreement") of even date herewith
pursuant to which the Company desires to sell to the Investors and the Investors
desire to purchase from the Company shares of the Company's Series C Preferred
Stock (the "Series C Stock"). A condition to the Investors' obligations under
the Purchase Agreement is that the Company, the Founders and the Investors enter
into this Agreement in order to provide the Founders and Investors with certain
rights to register shares of the Company's Common Stock, par value $0.01 per
share (the "Common Stock"), issuable upon conversion of the Series C Stock held
by them. In addition, certain Major Investors will be granted certain rights to
receive or inspect information pertaining to the Company, and a right of first
offer with respect to certain issuances by the Company of its securities. The
Company, the Investors and the Founders each desire to induce the Investors to
purchase shares of Series C Stock pursuant to the Purchase Agreement by agreeing
to the terms and conditions set forth herein. The Founders are holders of the
Company's Series A Preferred Stock (the "Series A Stock") or the Series B
Preferred Stock (the "Series B Stock," and together with the Series A Stock and
the Series C Stock the "Preferred Stock").
AGREEMENT
The parties hereby agree as follows:
1. Registration Rights. The Company and the Investors covenant and agree as
follows:
1.1 DEFINITIONS. For purposes of this Section 1:
(a) The terms "register," "registered," and "registration" refer
to a registration effected by preparing and filing a registration statement or
similar document in compliance with the Securities Act of 1933, as amended (the
"Securities Act"), and the declaration or ordering of effectiveness of such
registration statement or document;
(b) The term "Registrable Securities" means (i) the shares of
Common Stock issuable or issued upon conversion of the Preferred Stock, and (ii)
any other shares of Common
4
Stock of the Company issued as (or issuable upon the conversion or exercise of
any warrant, right or other security which is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of, the
shares listed in (i); provided, however, that the foregoing definition shall
exclude in all cases any Registrable Securities sold by a person in a
transaction in which his or her rights under this Agreement are not assigned.
Notwithstanding the foregoing, Common Stock or other securities shall only be
treated as Registrable Securities if and so long as they have not been (A) sold
to or through a broker or dealer or underwriter in a public distribution or a
public securities transaction, or (B) sold in a transaction exempt from the
registration and prospectus delivery requirements of the Securities Act under
Section 4(1) thereof so that all transfer restrictions, and restrictive legends
with respect thereto, if any, are removed upon the consummation of such sale;
(c) The number of shares of "Registrable Securities then
outstanding" shall be determined by the number of shares of Common Stock
outstanding which are, and the number of shares of Common Stock issuable
pursuant to then exercisable or convertible securities which are, Registrable
Securities;
(d) The term "Holder" means any person owning or having the
right to acquire Registrable Securities or any assignee thereof in accordance
with Section 1.12 of this Agreement;
(e) The term "Form S-3" means such form under the Securities Act
as in effect on the date hereof or any successor form under the Securities Act;
(f) The term "SEC" means the Securities and Exchange Commission;
and
(g) The term "Qualified IPO" means a firm commitment
underwritten public offering by the Company of shares of its Common Stock
pursuant to a registration statement on Form S-1 under the Securities Act, the
public offering price of which is not less than $12.00 per share (appropriately
adjusted for any stock split, dividend, combination or other recapitalization)
and which results in aggregate cash proceeds to the Company of at least
$20,000,000 (prior to underwriting discounts and commissions).
1.2 REQUEST FOR REGISTRATION.
(a) If the Company shall receive at any time after the 180th day
following the effective date of the first registration statement for a public
offering of securities of the Company (other than a registration statement
relating either to the sale of securities to employees of the Company pursuant
to a stock option, stock purchase or similar plan or an SEC Rule 145
transaction), a written request from the Holders of at least forty percent (40%)
of the Registrable Securities then outstanding that the Company file a
registration statement under the Securities Act, then the Company shall, within
ten (10) days of the receipt thereof, give written notice of such request to all
Holders and shall, subject to the limitations of subsection 1.2(b), use its best
efforts to effect as soon as practicable, and in any event within 60 days of the
receipt of such request, the registration under the Securities Act of all
Registrable Securities which the Holders request to be registered within twenty
(20) days of the mailing of such notice by the Company in accordance with
Section 3.3.
-2-
5
(b) If the Holders initiating the registration request hereunder
("Initiating Holders") intend to distribute the Registrable Securities covered
by their request by means of an underwriting, they shall so advise the Company
as a part of their request made pursuant to this Section 1.2 and the Company
shall include such information in the written notice referred to in subsection
1.2(a). The underwriter will be selected by a majority in interest of the
Initiating Holders and shall be reasonably acceptable to the Company. In such
event, the right of any Holder to include his Registrable Securities in such
registration shall be conditioned upon such Holder's participation in such
underwriting and the inclusion of such Holder's Registrable Securities in the
underwriting (unless otherwise mutually agreed by a majority in interest of the
Initiating Holders and such Holder) to the extent provided herein. All Holders
proposing to distribute their securities through such underwriting shall
(together with the Company as provided in subsection 1.5(e)) enter into an
underwriting agreement in customary form with the underwriter or underwriters
selected for such underwriting. Notwithstanding any other provision of this
Section 1.2, if the underwriter advises the Initiating Holders in writing that
marketing factors require a limitation of the number of shares to be
underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities which would otherwise be underwritten pursuant hereto,
and the number of shares of Registrable Securities that may be included in the
underwriting shall be allocated among all Holders thereof, including the
Initiating Holders, in proportion (as nearly as practicable) to the amount of
Registrable Securities of the Company owned by each Holder; provided, however,
that the number of shares of Registrable Securities to be included in such
underwriting shall not be reduced unless all other securities are first entirely
excluded from the underwriting.
(c) Notwithstanding the foregoing, if the Company shall furnish
to Holders requesting a registration statement pursuant to this Section 1.2, a
certificate signed by the President of the Company stating that in the good
faith judgment of the Board of Directors of the Company, it would be seriously
detrimental to the Company and its shareholders for such registration statement
to be filed and it is therefore essential to defer the filing of such
registration statement, the Company shall have the right to defer such filing
for a period of not more than 120 days after receipt of the request of the
Initiating Holders; provided, however, that the Company may not utilize this
right more than once in any twelve-month period.
(d) In addition, the Company shall not be obligated to effect,
or to take any action to effect, any registration pursuant to this Section 1.2:
(i) After the Company has effected two (2) registrations
pursuant to this Section 1.2 and such registrations have been declared or
ordered effective;
(ii) If the aggregate offering price to the public, as
shown on the cover of the registration statement, of the Registrable Securities
to be registered would be less than $7,500,000;
(iii) During the period starting with the date sixty
(60) days prior to the Company's good faith estimate of the date of filing of,
and ending on a date one hundred eighty (180) days after the effective date of,
a registration subject to Section 1.3 hereof; provided that the Company is
actively employing in good faith all reasonable efforts to cause such
registration
-3-
6
statement to become effective; and provided further that the Company notifies
the Initiating Holders within 20 days of their request for registration of its
intention to file such a registration within 60 days of the Company's notice; or
(iv) If the Initiating Holders propose to dispose of
shares of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Section 1.4 below.
1.3 COMPANY REGISTRATION. If (but without any obligation to do so) the
Company proposes to register (including for this purpose a registration effected
by the Company for shareholders other than the Holders) any of its stock under
the Securities Act in connection with the public offering of such securities
solely for cash (other than a registration relating solely to the sale of
securities to participants in a Company stock plan or a transaction covered by
Rule 145 under the Securities Act), the Company shall, at such time, promptly
give each Holder written notice of such registration. Upon the written request
of each Holder given within twenty (20) days after mailing of such notice by the
Company in accordance with Section 3.3, the Company shall, subject to the
provisions of Section 1.8, cause to be registered under the Securities Act all
of the Registrable Securities that each such Holder has requested to be
registered.
1.4 FORM S-3 REGISTRATION. In case the Company shall receive from any
Holder or Holders of Registrable Securities representing not less than 500,000
shares of Common Stock (as adjusted for stock splits, stock dividends and stock
combinations) a written request or requests that the Company effect a
registration on Form S-3 and any related qualification or compliance with
respect to all or a part of the Registrable Securities owned by such Holder or
Holders, the Company will:
(a) promptly give written notice of the proposed registration,
and any related qualification or compliance, to all other Holders; and
(i) as soon as practicable, effect such registration and
all such qualifications and compliances as may be so requested and as would
permit or facilitate the sale and distribution of all or such portion of such
Holder's or Holders' Registrable Securities as are specified in such request,
together with all or such portion of the Registrable Securities of any other
Holder or Holders joining in such request as are specified in a written request
given within 15 days after receipt of such written notice from the Company;
provided, however, that the Company shall not be obligated to effect any such
registration, qualification or compliance, pursuant to this Section 1.4: (i) if
Form S-3 is not available for such offering by the Holders; (ii) if the Holders,
together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such
other securities (if any) at an aggregate price to the public (net of any
underwriters' discounts or commissions) of less than $1,000,000; (iii) if the
Company shall furnish to the Holders a certificate signed by the President of
the Company stating that in the good faith judgment of the Board of Directors of
the Company, it would be seriously detrimental to the Company and its
shareholders for such Form S-3 Registration to be effected at such time, in
which event the Company shall have the right to defer the filing of the Form S-3
registration statement for a period of not more than 120
-4-
7
days after receipt of the request of the Holder or Holders under this Section
1.4; provided, however, that the Company shall not utilize this right more than
once in any twelve month period; (iv) after the Company has effected two (2)
registrations pursuant to this Section 1.4 and such registrations have been
declared or ordered effective; (v) if the Company has, within the six (6) month
period preceding the date of such request, already effected a registration on
Form S-3 for the Holders pursuant to this Section 1.4; (vi) in any particular
jurisdiction in which the Company would be required to qualify to do business or
to execute a general consent to service of process in effecting such
registration, qualification or compliance; or (vii) during the period ending one
hundred eighty (180) days after the effective date of a registration statement
subject to Section 1.3.
(b) Subject to the foregoing, the Company shall file a
registration statement covering the Registrable Securities and other securities
so requested to be registered as soon as practicable after receipt of the
request or requests of the Holders. Registrations effected pursuant to this
Section 1.4 shall not be counted as demands for registration or registrations
effected pursuant to Sections 1.2 or 1.3, respectively.
1.5 OBLIGATIONS OF THE COMPANY. Whenever required under this Section 1
to effect the registration of any Registrable Securities, the Company shall, as
expeditiously as reasonably possible:
(a) Prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use its best efforts to cause such
registration statement to become effective, and, upon the request of the Holders
of a majority of the Registrable Securities registered thereunder, keep such
registration statement effective for up to one hundred twenty (120) days. The
Company shall not be required to file, cause to become effective or maintain the
effectiveness of any registration statement that contemplates a distribution of
securities on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act.
(b) Prepare and file with the SEC such amendments and
supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the
provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement for up to one hundred twenty
(120) days.
(c) Furnish to the Holders such numbers of copies of a
prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents as they may
reasonably request in order to facilitate the disposition of Registrable
Securities owned by them.
(d) Use its best efforts to register and qualify the securities
covered by such registration statement under such other securities or blue sky
laws of such jurisdictions as shall be reasonably requested by the Holders,
provided that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions.
-5-
8
(e) In the event of any underwritten public offering, enter into
and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering. Each Holder
participating in such underwriting shall also enter into and perform its
obligations under such an agreement.
(f) Notify each Holder of Registrable Securities covered by such
registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event
as a result of which the prospectus included in such registration statement, as
then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances then
existing, such obligation to continue for one hundred twenty (120) days. The
Company will use reasonable efforts to amend or supplement such prospectus in
order to cause such prospectus not to include any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary
to make the statements therein not misleading in the light of the circumstances
then existing.
(g) Cause all such Registrable Securities registered pursuant
hereunder to be listed on each securities exchange on which similar securities
issued by the Company are then listed.
(h) Provide a transfer agent and registrar for all Registrable
Securities registered pursuant hereunder and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such
registration.
(i) Use its best efforts to furnish, at the request of any
Holder requesting registration of Registrable Securities pursuant to this
Section 1, on the date that such Registrable Securities are delivered to the
underwriters for sale in connection with a registration pursuant to this Section
1, if such securities are being sold through underwriters, (i) an opinion, dated
such date, of the counsel representing the Company for the purposes of such
registration, in form and substance as is customarily given to underwriters in
an underwritten public offering, addressed to the underwriters, and (ii) a
letter dated such date, from the independent certified public accountants of the
Company, in form and substance as is customarily given by independent certified
public accountants to underwriters in an underwritten public offering, addressed
to the underwriters.
1.6 FURNISH INFORMATION. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 1 with
respect to the Registrable Securities of any selling Holder that such Holder
shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities
as shall be required to effect the registration of such Holder's Registrable
Securities. The Company shall have no obligation with respect to any
registration requested pursuant to Section 1.2 or Section 1.4 of this Agreement
if, as a result of the application of the preceding sentence, the number of
shares or the anticipated aggregate offering price of the Registrable Securities
to be included in the registration does not equal or exceed the number of shares
or the anticipated aggregate offering price required to originally trigger the
Company's obligation to
-6-
9
initiate such registration as specified in subsection 1.2(d) or subsection
1.4(b), whichever is applicable.
1.7 EXPENSES OF REGISTRATION.
(a) DEMAND REGISTRATION AND REGISTRATION ON FORM S-3. All
expenses other than underwriting discounts and commissions incurred in
connection with registrations, filings or qualifications pursuant to Sections
1.2 and 1.4, including (without limitation) all registration, filing and
qualification fees, printers' and accounting fees, fees and disbursements of
counsel for the Company, and the reasonable fees and disbursements of one
counsel for the selling Holders selected by them with the approval of the
Company, which approval shall not be unreasonably withheld, shall be borne by
the Company; provided, however, that the Company shall not be required to pay
for any expenses of any registration proceeding begun pursuant to Section 1.2 or
Section 1.4 if the registration request is subsequently withdrawn at the request
of the Holders who requested registration (in which case all participating
Holders shall bear such expenses), unless (i) in the case of a registration
pursuant to Section 1.2, the Holders of at least forty percent (40%) of the
Registrable Securities then outstanding agree to forfeit their right to one
demand registration pursuant to Section 1.2, or (ii) the withdrawal is based
upon material adverse information concerning the Company of which the Holders
were not aware at the time of such request.
(b) COMPANY REGISTRATION. All expenses other than underwriting
discounts and commissions incurred in connection with registrations, filings or
qualifications of Registrable Securities pursuant to Section 1.3 for each Holder
(which right may be assigned as provided in Section 1.12), including (without
limitation) all registration, filing, and qualification fees, printers' and
accounting fees, fees and disbursements of counsel for the Company and the
reasonable fees and disbursements of one counsel for the selling Holder or
Holders selected by them with the approval of the Company, which approval shall
not be unreasonably withheld, shall be borne by the Company.
1.8 UNDERWRITING REQUIREMENTS. In connection with any offering involving
an underwriting of shares of the Company's capital stock, the Company shall not
be required under Section 1.3 to include any of the Holders' securities in such
underwriting unless they accept the terms of the underwriting as agreed upon
between the Company and the underwriters selected by it (or by other persons
entitled to select the underwriters), and then only in such quantity as the
underwriters determine in their sole discretion will not jeopardize the success
of the offering by the Company. If the total amount of securities, including
Registrable Securities, requested by shareholders to be included in such
offering exceeds the amount of securities sold other than by the Company that
the underwriters determine in their sole discretion is compatible with the
success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities,
which the underwriters determine in their sole discretion will not jeopardize
the success of the offering (the securities so included to be apportioned pro
rata among the selling shareholders according to the total amount of securities
entitled to be included therein owned by each selling shareholder or in such
other proportions as shall mutually be agreed to by such selling shareholders)
but in no event shall the amount of securities of the selling Holders included
in the offering be reduced below thirty percent (30%) of
-7-
10
the total amount of securities included in such offering, unless such offering
is the initial public offering of the Company's securities, in which case, the
selling shareholders may be excluded if the underwriters make the determination
described above and no other shareholder's securities are included. For purposes
of the preceding parenthetical concerning apportionment, for any selling
shareholder which is a holder of Registrable Securities and which is a
partnership or corporation, the partners, retired partners and shareholders of
such holder, or the estates and family members of any such partners and retired
partners and any trusts for the benefit of any of the foregoing persons shall be
deemed to be a single "selling shareholder," and any pro-rata reduction with
respect to such "selling shareholder" shall be based upon the aggregate amount
of shares carrying registration rights owned by all entities and individuals
included in such "selling shareholder," as defined in this sentence.
1.9 DELAY OF REGISTRATION. No Holder shall have any right to obtain or
seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 1.
1.10 INDEMNIFICATION. In the event any Registrable Securities are
included in a registration statement under this Section 1:
(a) To the extent permitted by law, the Company will indemnify
and hold harmless each Holder, any underwriter (as defined in the Securities
Act) for such Holder and each person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), against any losses, claims,
damages, or liabilities (joint or several) to which they may become subject
under the Securities Act, the Exchange Act or other federal or state law,
insofar as such losses, claims, damages, or liabilities (or actions in respect
thereof) arise out of or are based upon any of the following statements,
omissions or violations (collectively a "Violation"): (i) any untrue statement
or alleged untrue statement of a material fact contained in such registration
statement, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto, (ii) the omission or alleged
omission to state therein a material fact required to be stated therein, or
necessary to make the statements therein not misleading, or (iii) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act, any
state securities law or any rule or regulation promulgated under the Securities
Act, the Exchange Act or any state securities law; and the Company will pay to
each such Holder, underwriter or controlling person, as incurred, any legal or
other expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, liability, or action; provided, however,
that the indemnity agreement contained in this subsection 1.10(a) shall not
apply to amounts paid in settlement of any such loss, claim, damage, liability,
or action if such settlement is effected without the consent of the Company
(which consent shall not be unreasonably withheld), nor shall the Company be
liable to any Holder, underwriter or controlling person for any such loss,
claim, damage, liability, or action to the extent that it arises out of or is
based upon a Violation which occurs in reliance upon and in conformity with
written information furnished expressly for use in connection with such
registration by any such Holder, underwriter or controlling person.
-8-
11
(b) To the extent permitted by law, each selling Holder will
indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the registration statement, each person, if any, who
controls the Company within the meaning of the Securities Act, any underwriter,
any other Holder selling securities in such registration statement and any
controlling person of any such underwriter or other Holder, against any losses,
claims, damages, or liabilities (joint or several) to which any of the foregoing
persons may become subject, under the Securities Act, the Exchange Act or other
federal or state law, insofar as such losses, claims, damages, or liabilities
(or actions in respect thereto) arise out of or are based upon any Violation, in
each case to the extent (and only to the extent) that such Violation occurs in
reliance upon and in conformity with written information furnished by such
Holder under an instrument duly executed by such Holder and stated to be
expressly for use in connection with such registration; and each such Holder
will pay, as incurred, any legal or other expenses reasonably incurred by any
person intended to be indemnified pursuant to this subsection 1.10(b), in
connection with investigating or defending any such loss, claim, damage,
liability, or action; provided, however, that the indemnity agreement contained
in this subsection 1.10(b) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected
without the consent of the Holder, which consent shall not be unreasonably
withheld; provided, that in no event shall any indemnity under this subsection
1.10(b) exceed the net proceeds from the offering received by such Holder.
(c) Promptly after receipt by an indemnified party under this
Section 1.10 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 1.10, deliver to
the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
(together with all other indemnified parties which may be represented without
conflict by one counsel) shall have the right to retain one separate counsel,
with the reasonable fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such
counsel in such proceeding. The failure to deliver written notice to the
indemnifying party within a reasonable time of the commencement of any such
action, if materially prejudicial to its ability to defend such action, shall
relieve such indemnifying party of any liability to the indemnified party under
this Section 1.10, but the omission so to deliver written notice to the
indemnifying party will not relieve it of any liability that it may have to any
indemnified party otherwise than under this Section 1.10. No Indemnifying Party,
in the defense of any such claim or litigation, shall except with the consent of
each Indemnified Party, consent to entry of any judgment or enter into any
settlement which does not include as an unconditional term thereof the giving by
the claimant or plaintiff to such Indemnified Party of a release from all
liability in respect to such claim or litigation.
(d) If the indemnification provided for in this Section 1.10 is
held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any loss, liability, claim, damage or expense referred to
therein, then the indemnifying party, in lieu of
-9-
12
indemnifying such indemnified party hereunder, shall contribute to the amount
paid or payable by such indemnified party as a result of such loss, liability,
claim, damage, or expense in such proportion as is appropriate to reflect the
relative fault of the indemnifying party on the one hand and of the indemnified
party on the other in connection with the statements or omissions that resulted
in such loss, liability, claim, damage or expense as well as any other relevant
equitable considerations; provided, that in no event shall any contribution by a
Holder under this Subsection 1.10(d) exceed the net proceeds from the offering
received by such Holder. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties' relative intent,
knowledge, access to information, and opportunity to correct or prevent such
statement or omission.
(e) The obligations of the Company and Holders under this
Section 1.10 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Section 1, and otherwise.
1.11 REPORTS UNDER SECURITIES EXCHANGE ACT OF 1934. With a view to
making available to the Holders the benefits of Rule 144 promulgated under the
Securities Act and any other rule or regulation of the SEC that may at any time
permit a Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to:
(a) make and keep public information available, as those terms
are understood and defined in SEC Rule 144, at all times after ninety (90) days
after the effective date of the first registration statement filed by the
Company for the offering of its securities to the general public so long as the
Company remains subject to the periodic reporting requirements under Sections 13
or 15(d) of the Exchange Act;
(b) take such action, including the voluntary registration of
its Common Stock under Section 12 of the Exchange Act, as is necessary to enable
the Holders to utilize Form S-3 for the sale of their Registrable Securities,
such action to be taken as soon as practicable after the end of the fiscal year
in which the first registration statement filed by the Company for the offering
of its Common Stock to the general public is declared effective;
(c) file with the SEC in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act;
and
(d) furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (i) a written statement by the
Company that it has complied with the reporting requirements of SEC Rule 144 (at
any time after ninety (90) days after the effective date of the first
registration statement filed by the Company), the Securities Act and the
Exchange Act (at any time after it has become subject to such reporting
requirements), or that it qualifies as a registrant whose securities may be
resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of
the most recent annual or quarterly report of the Company and such other reports
and documents so filed by the Company, and (iii) such other information as may
be
-10-
13
reasonably requested in availing any Holder of any rule or regulation of the SEC
which permits the selling of any such securities without registration or
pursuant to such form.
1.12 ASSIGNMENT OF REGISTRATION RIGHTS. The rights to cause the Company
to register Registrable Securities pursuant to this Section 1 may be assigned
(but only with all related obligations) by a Holder to a transferee or assignee
of at least 10,000 shares of such securities, provided the Company is, within a
reasonable time after such transfer, furnished with written notice of the name
and address of such transferee or assignee and the securities with respect to
which such registration rights are being assigned; and provided, further, that
such assignment shall be effective only if immediately following such transfer
the further disposition of such securities by the transferee or assignee is
restricted under the Securities Act. For the purposes of determining the number
of shares of Registrable Securities held by a transferee or assignee, the
holdings of transferees and assignees of a partnership who are partners or
retired partners of such partnership (including spouses and ancestors, lineal
descendants and siblings of such partners or spouses who acquire Registrable
Securities by gift, will or intestate succession) shall be aggregated together
and with the partnership; provided that all assignees and transferees who would
not qualify individually for assignment of registration rights shall have a
single attorney-in-fact for the purpose of exercising any rights, receiving
notices or taking any action under Section 1.
1.13 LIMITATIONS ON SUBSEQUENT REGISTRATION RIGHTS. From and after the
date of this Agreement, the Company shall not, without the prior written consent
of the Holders of a majority of the outstanding Registrable Securities, enter
into any agreement with any holder or prospective holder of any securities of
the Company which would allow such holder or prospective holder (a) to include
such securities in any registration filed under Section 1.2 hereof, unless under
the terms of such agreement, such holder or prospective holder may include such
securities in any such registration only to the extent that the inclusion of his
securities will not reduce the amount of the Registrable Securities of the
Holders which is included or (b) to make a demand registration which could
result in such registration statement being declared effective prior to the date
set forth in subsection 1.2(a) or within one hundred twenty (120) days of the
effective date of any registration effected pursuant to Section 1.2.
1.14 MARKET-STANDOFF AGREEMENT.
(a) MARKET-STANDOFF PERIOD; AGREEMENT. In connection with the
initial public offering of the Company's securities and upon request of the
Company or the underwriters managing such offering of the Company's securities,
each Holder agrees not to sell, make any short sale of, loan, grant any option
for the purchase of, or otherwise dispose of any securities of the Company
(other than those included in the registration) without the prior written
consent of the Company or such underwriters, as the case may be, for such period
of time (not to exceed 180 days) from the effective date of such registration as
may be requested by the Company or such managing underwriters and to execute an
agreement reflecting the foregoing as may be requested by the underwriters at
the time of the Company's initial public offering. In addition, the Holder
agrees to be bound by similar restrictions, and to sign a similar agreement, in
connection with any one (but only one) additional registration statement filed
within 12 months after the closing date of the initial public offering, provided
that the duration of the market-standoff period with
-11-
14
respect to such additional registration shall not exceed 90 days from the
effective date of such additional registration.
(b) LIMITATIONS. The obligations described in Section 1.14(a)
shall apply only if all officers and directors of the Company and all persons
holding 1% or more of the Common Stock (on a fully-diluted basis) enter into
similar agreements, and shall not apply to a registration relating solely to
employee benefit plans, or to a registration relating solely to a transaction
pursuant to Rule 145 under the Securities Act.
(c) STOP-TRANSFER INSTRUCTIONS. In order to enforce the
foregoing covenants, the Company may impose stop-transfer instructions with
respect to the securities of each Holder (and the securities of every other
person subject to the restrictions in Section 1.14(a)).
(d) TRANSFEREES BOUND. Each Holder agrees that it will not
transfer securities of the Company unless each transferee agrees in writing to
be bound by all of the provisions of this Section 1.14, provided that this
Section 1.14(d) shall not apply to transfers pursuant to a registration
statement.
1.15 TERMINATION OF REGISTRATION RIGHTS. No Holder shall be entitled to
exercise any right provided for in this Section 1 after the earlier of (i) five
(5) years following the consummation of a Qualified IPO, or (ii) with respect to
any Holder, such time following a Qualified IPO as the Holder owns less than 1%
of the Common Stock (on an as-converted, fully diluted basis) and Rule 144 or
another similar exemption under the Securities Act is available for the sale of
all of such Holder's shares during a three (3)-month period without
registration.
2. COVENANTS OF THE COMPANY.
2.1 DELIVERY OF FINANCIAL STATEMENTS. The Company shall deliver to each
Major Investor (as hereinafter defined):
(a) as soon as practicable, but in any event within ninety (90)
days after the end of each fiscal year of the Company, an income statement for
such fiscal year, a balance sheet of the Company and statement of shareholder's
equity as of the end of such year, and a statement of cash flows for such year,
such year-end financial reports to be in reasonable detail, prepared in
accordance with generally accepted accounting principles ("GAAP"), and audited
and certified by an independent public accounting firm of nationally recognized
standing selected by the Company;
(b) as soon as practicable, but in any event within thirty (30)
days after the end of each of the first three (3) quarters of each fiscal year
of the Company, an unaudited profit or loss statement, a statement of cash flows
for such fiscal quarter and an unaudited balance sheet as of the end of such
fiscal quarter;
(c) as soon as practicable, but in any event twenty (20) days
prior to the end of each fiscal year, a budget and business plan for the next
fiscal year; and
-12-
15
(d) with respect to the financial statements called for in
subsection (b) of this Section 2.1, an instrument executed by the Chief
Financial Officer or President of the Company certifying that such financials
were prepared in accordance with GAAP consistently applied with prior practice
for earlier periods (with the exception of footnotes that may be required by
GAAP) and fairly present the financial condition of the Company and its results
of operation for the period specified, subject to year-end audit adjustment,
provided that the foregoing shall not restrict the right of the Company to
change its accounting principles consistent with GAAP, if the Board of Directors
determines that it is in the best interest of the Company to do so.
"Major Investor" shall mean any person who together with
any general partners or other affiliates of such person, holds securities
representing (on an as-converted basis) not less than 500,000 shares of Common
Stock (as adjusted for stock splits, stock dividends and stock combinations).
2.2 INSPECTION. The Company shall permit each Major Investor, at the
Major Investor's expense, to visit and inspect the Company's properties, to
examine its books of account and records and to discuss the Company's affairs,
finances and accounts with its officers, all at such reasonable times as may be
requested by the Major Investor; provided, however, that the Company shall not
be obligated pursuant to this Section 2.2 to provide access to any information
which it reasonably considers to be a trade secret or similar confidential
information.
2.3 RESERVATION OF COMMON STOCK. The Company will at all times reserve
and keep available, solely for issuance and delivery upon the conversion of the
Preferred Stock, all Common Stock issuable from time to time upon such
conversion.
2.4 PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT. The Company shall
require all managerial and technical personnel to execute an agreement regarding
confidentiality and proprietary information substantially in the form or forms
delivered to the counsel for the Investors.
2.5 RIGHT OF FIRST OFFER. Subject to the terms and conditions specified
in this Section 2.5, the Company hereby grants to each Major Investor a right of
first offer with respect to future sales by the Company of its Shares (as
hereinafter defined). A Major Investor who chooses to exercise the right of
first offer may designate as purchasers under such right itself or its partners
or affiliates in such proportions as it deems appropriate.
Each time the Company proposes to offer any shares of, or
securities convertible into or exercisable for any shares of, or any security
carrying any warrant or right to subscribe to purchase, any class of its capital
stock, or any such warrant or right ("Shares"), the Company shall first make an
offering of such Shares to each Major Investor in accordance with the following
provisions:
(a) The Company shall deliver a notice by certified mail
("Notice") to the Major Investors stating (i) its bona fide intention to offer
such Shares, (ii) the number of such Shares to be offered, and (iii) the price
and terms, if any, upon which it proposes to offer such Shares.
-13-
16
(b) Within 15 calendar days after delivery of the Notice, the
Major Investor may elect to purchase or obtain, at the price and on the terms
specified in the Notice, up to that portion of such Shares which equals the
proportion that the number of shares of Common Stock issued and held, or
issuable upon conversion and exercise of all convertible or exercisable
securities then held, by such Major Investor bears to the total number of shares
of Common Stock then outstanding (assuming full conversion and exercise of all
convertible or exercisable securities). The Company shall promptly, in writing,
inform each Major Investor that purchases all the shares available to it (each,
a "Fully-Exercising Investor") of any other Major Investor's failure to do
likewise. During the ten (10)-day period commencing after receipt of such
information, each Fully-Exercising Investor shall be entitled to obtain that
portion of the Shares for which Major Investors were entitled to subscribe but
which were not subscribed for by the Major Investors that is equal to the
proportion that the number of shares of Common Stock issued and held, or
issuable upon conversion and exercise of all convertible or exercisable
securities then held, by such Fully-Exercising Investor bears to the total
number of shares of Common Stock issued and held, or issuable upon conversion
and exercise of all convertible or exercisable securities then held, by all
Fully-Exercising Investors.
(c) The Company may, during the 45-day period following the
expiration of the period provided in subsection 2.5(b) hereof, offer the
remaining unsubscribed portion of the Shares to any person or persons at a price
not less than, and upon terms no more favorable to the offeree than those
specified in the Notice. If the Company does not enter into an agreement for the
sale of the Shares within such period, or if such agreement is not consummated
within 45 days of the execution thereof, the right provided hereunder shall be
deemed to be revived and such Shares shall not be offered unless first reoffered
to the Major Investors in accordance herewith.
(d) The right of first offer in this paragraph 2.5 shall not be
applicable (i) to the issuance or sale of up to 2,200,000 shares (or such
greater number as is unanimously approved by the Board of Directors) of Common
Stock (or options therefor) to employees, consultants and directors, pursuant to
plans or agreements approved by the Board of Directors for the primary purpose
of soliciting or retaining their services, (ii) to or after consummation of a
Qualified IPO, (iii) to the issuance of securities pursuant to the conversion or
exercise of convertible or exercisable securities, (iv) to the issuance of
securities in connection with a bona fide business acquisition of or by the
Company, whether by merger, consolidation, sale of assets, sale or exchange of
stock or otherwise, (v) to the issuance of securities to financial institutions
or lessors in connection with commercial credit arrangements, equipment
financings, or similar transactions, (vi) to the issuance or sale of the Series
C Stock, or (vii) to the issuance of securities that, with unanimous approval of
the Board of Directors of the Company, are not offered to any existing
shareholder of the Company.
(e) Notwithstanding the foregoing, the right of first offer in
this Section 2.5 shall terminate with respect to any Major Investor who fails to
purchase all of such Major Investor's pro rata amount of Shares allocated to
such Major Investor pursuant to this Section 2.5.
-14-
17
2.6 COMPANY RIGHT OF FIRST OFFER. No holder of Preferred Stock
(or a Permitted Transferee, as defined below) may sell or dispose, for value, of
any interest (a "Proposed Sale"), in any shares of Preferred Stock (the
"Shares"), other than to a Permitted Transferee, unless such holder (the
"Selling Holder") delivers a notice (the "Notice") to the Company at least 10
business days prior to the Proposed Sale setting forth the material terms and
conditions of the Proposed Sale including, without limitation, the number of
Shares proposed to be sold or transferred, and the form and amount of
consideration to be paid.
(a) At any time within 10 business days from the date such
Notice is received by the Company, the Company shall have the right to deliver
to the Selling Holder notice of its irrevocable commitment to purchase all (but
not less than all) of the Shares at the same price and upon the same terms as
the Selling Holder proposes to sell the Shares in the Notice. If the Company
delivers to the Selling Holder notice of such irrevocable commitment within such
10-business-day period, the Company and the Selling Holder agree to execute a
definitive agreement with respect to the Proposed Sale within 45 days from the
date of the Company's notice. If the Company does not deliver to the Selling
Holder notice of such irrevocable commitment within such 10-business-day period,
then the Selling Holder shall have 90 days from the end of such period within
which to sell the Shares upon terms not materially less favorable to the Selling
Holder than those terms set forth in the Notice. If such 90-day period shall
expire without such a sale having been consummated, or if the Selling Holder
proposes to sell the Shares upon terms materially less favorable to the Selling
Holder than those terms set forth in the Notice, the Selling Holder shall again
comply with the procedures set forth in this Section 2.6.
(b) "Permitted Transferee" shall mean any affiliate (as such
term is defined in Rule 405 promulgated under the Securities Act), partner,
member, beneficiary (in the case of a trust), family member, trust for the
benefit of family members, or family limited partnership. This Section 2.6 shall
not apply to any transfer by gift, will, or intestacy, or to any assignment by
operation of law or merger.
(c) Each certificate representing shares of Preferred Stock
shall bear the following legend:
"THE SHARES EVIDENCED HEREBY ARE SUBJECT TO CERTAIN RESTRICTIONS
ON TRANSFER AS SET FORTH IN AN INVESTORS' RIGHTS AGREEMENT BY
AND AMONG THE COMPANY AND ITS STOCKHOLDERS (A COPY OF WHICH MAY
BE OBTAINED FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN
SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BECOME
BOUND BY ALL THE PROVISIONS OF SAID INVESTORS' RIGHTS
AGREEMENT."
2.7 TERMINATION OF COVENANTS.
(a) The covenants set forth in Sections 2.1 through Section 2.6
shall terminate as to each Investor and be of no further force or effect (i)
immediately prior to the consummation of a Qualified IPO, or (ii) when the
Company shall sell, convey, or otherwise dispose of or encumber all or
substantially all of its property or business or merge into or consolidate with
any
-15-
18
other corporation (other than a wholly-owned subsidiary corporation) or effect
any other transaction or series of related transactions in which more than fifty
percent (50%) of the voting power of the Company is disposed of, provided that
this subsection (ii) shall not apply to a merger effected exclusively for the
purpose of changing the domicile of the Corporation.
(b) The covenants set forth in Sections 2.1 and 2.2 shall
terminate as to each Holder and be of no further force or effect when the
Company first becomes subject to the periodic reporting requirements of Sections
13 or 15(d) of the Exchange Act, if this occurs earlier than the events
described in Section 2.7(a) above.
3. MISCELLANEOUS.
3.1 SUCCESSORS AND ASSIGNS. Except as otherwise provided in this
Agreement, the terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective permitted successors and assigns of the
parties (including transferees of any of the Series C Preferred Stock or any
Common Stock issued upon conversion thereof). Nothing in this Agreement, express
or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.
3.2 AMENDMENTS AND WAIVERS. Any term of this Agreement may be amended or
waived only with the written consent of the Company and the holders of 80% of
the Registrable Securities then outstanding; provided that if such amendment has
the effect of affecting the Founders (i) in a manner different than securities
issued to the Investors and (ii) in a manner adverse to the interests of either
of the Founders, then such amendment shall require the consent of the affected
Founder. Any amendment or waiver effected in accordance with this paragraph
shall be binding upon each holder of any Registrable Securities then
outstanding, each future holder of all such Registrable Securities, and the
Company.
3.3 NOTICES. Unless otherwise provided, any notice required or permitted
by this Agreement shall be in writing and shall be deemed sufficient upon
delivery, when delivered personally or by overnight courier or sent by telegram
or fax, or five days after being deposited in the U.S. mail, as certified or
registered mail, with postage prepaid, return receipt requested, and addressed
to the party to be notified at such party's address or fax number as set forth
below or on Exhibit A hereto or as subsequently modified by written notice.
3.4 SEVERABILITY. If one or more provisions of this Agreement are held
to be unenforceable under applicable law, the parties agree to renegotiate such
provision in good faith. In the event that the parties cannot reach a mutually
agreeable and enforceable replacement for such provision, then (a) such
provision shall be excluded from this Agreement, (b) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (c) the
balance of the Agreement shall be enforceable in accordance with its terms.
3.5 GOVERNING LAW. This Agreement and all acts and transactions pursuant
hereto shall be governed, construed and interpreted in accordance with the laws
of the State of California, without giving effect to principles of conflicts of
laws.
-16-
19
3.6 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
3.7 TITLES AND SUBTITLES. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.
3.8 AGGREGATION OF STOCK. All shares of the Preferred Stock held or
acquired by affiliated entities or persons shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement.
[Signature Page Follows]
-17-
20
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC.
-----------------------------------------
(Investor)
By: /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ By:
------------------------------ -------------------------------------
Name:
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
21
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC.
-----------------------------------------
(Investor)
By: By:
------------------------------ -------------------------------------
Name:
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
By: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
Title: Secretary
Address: ▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Fax: ▇▇▇-▇▇▇-▇▇▇▇
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
22
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC.
-----------------------------------------
(Investor)
By: By:
------------------------------ -------------------------------------
Name:
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
23
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
IDS Life Series Fund, Inc. -- Equity
Portfolio
DIADEXUS, INC. (Investor)
By: By: /s/ ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Vice President
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
24
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
AXP Strategy Series, Inc.-- AXP
Strategy Aggressive Fund
DIADEXUS, INC. (Investor)
By: By: /s/ ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Vice President
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
25
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
AXP Variable Portfolio, Inc. -- AXP
Strategy Aggressive Fund
DIADEXUS, INC. (Investor)
By: By: /s/ ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Vice President
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
26
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
BAVP, L.P.
By: BA Venture Partners VI, LLC
DIADEXUS, INC. its General Partner
-----------------------------------------
(Investor)
By: By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Managing Member
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
27
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
By: ▇▇▇▇▇ Global Investments, Ltd.
DIADEXUS, INC. By: ▇▇▇▇▇ Capital Management, Inc.
By: By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Trading Manager
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
28
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. -----------------------------------------
(Investor)
By: By:
------------------------------ -------------------------------------
Name:
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS: REMINGTON INVESTMENT STRATEGIES, L.P.
By: ▇▇▇▇▇ Capital Advisors, L.L.C.
General Partner
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
-----------------------------------------
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
Address:
Title: Director of Operations
----------------------------------
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
29
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
By: ▇▇▇▇▇ Global Fixed Income Fund, Ltd.
DIADEXUS, INC. By: ▇▇▇▇▇ Capital Management, Inc.
By: By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Director of Operations
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
30
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. Brookside Capital Partners Fund, L.P.
-----------------------------------------
(Investor)
By: By: /s/ ▇▇ ▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇ ▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Managing Director
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
31
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
RHO Management Trust I
By: Rho Management Company, Inc.
DIADEXUS, INC. Investment Advisor
By: By: /s/ ▇▇▇▇ Leschley
------------------------------ -------------------------------------
Name: ▇▇▇▇ Leschley
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Managing Director
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
32
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. Bay Star Capital, L.P.
-----------------------------------------
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Member - Investment Manager
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
33
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. Bay Star Capital, LTD
-----------------------------------------
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Member - Investment Manager
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
34
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ESSEX PRIVATE PLACEMENT FUND III A
Limited Partnership
By: By: Essex Investment Management
------------------------------ Company, LLC its General Partner
By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Principal
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
35
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ESSEX PRIVATE PLACEMENT FUND III B
Limited Partnership
By: By: Essex Investment Management
------------------------------ Company, LLC its General Partner
By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Principal
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
36
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. THE ▇▇▇▇▇▇▇▇ FUND, INC.
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Chairman
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
37
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. FOUR PARTNERS
(Investor)
By: By: /s/ ▇▇▇ ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇ ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Trustee
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
38
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇ / TISCH INVESTMENT
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Managing Member of Managing Member
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
39
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. FBB ASSOCIATES
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇▇▇▇▇
----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Partner
---------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
40
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
BRITISH AIRWAYS PENSION
DIADEXUS, INC. TRUSTEES
(Investor)
By: By: /s/ ▇▇▇▇ ▇▇▇▇▇ /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Authorized Signatories
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
41
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. MCP GLOBAL CORP. LTD.
(Investor)
By: By: /s/ ▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Director
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
42
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. EAG ENTERPRISES LTD.
(Investor)
By: By: /s/ ▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Investment Manager
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
43
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. CLOSEFIRE LTD.
(Investor)
By: By: /s/ ▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Investment Manager
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
44
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Investment Manager
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
45
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. CODITEC INTL LTD - LION
(Investor)
By: By: /s/ ▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Investment Manager
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
46
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. LOMBARD ODIER & CIE
(Investor)
By: By: /s/ C. Gokok /s/ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ Gokok / ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Assistant Vice Presidents
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
47
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. NARRAGANSETT I LP
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ III
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ III
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Managing Member
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
48
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. NARRAGANSETT OFFSHORE, LTD.
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ III
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ III
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Managing Member
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
49
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. BLUE RIDGE LIMITED PARTNERSHIP
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: MD
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
50
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. BLUE RIDGE PRIVATE EQUITY FUND
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: MD
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
51
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. -----------------------------------------
(Investor)
By: By:
------------------------------ -------------------------------------
Name:
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS: BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF PARTNERS L.P.,
its General Partner
---------------------------------- By: BVF, INC., its General Partner
SmithKline ▇▇▇▇▇▇▇ Corporation
By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-------------------------------------
President
Address:
BIOTECHNOLOGY VALUE FUND II, L.P.
By: BVF PARTNERS L.P.,
Fax: its General Partner
By: BVF, INC., its General Partner
----------------------------------
Incyte Pharmaceuticals, Inc. By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-------------------------------------
President
Address: INVESTMENT 10 L.L.C.
By: BVF PARTNERS, L.P.,
Fax: Its Investment Advisor
By: BVF, INC., its General Partner
By: /s/ ▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-------------------------------------
President
52
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ADMIRALS, L.P.
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: COO
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
53
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
-----------------------------------------
(Investor)
By: By: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: Quota Rabbico II, Ltd.
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: President
-----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
54
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
-----------------------------------------
(Investor)
By: By: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: Argonaut Partnership, L.P.
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: President
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
55
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
-----------------------------------------
(Investor)
By: By: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: Argonaut Investment Fund, Ltd.
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: President
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
56
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
-----------------------------------------
(Investor)
By: By:
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
57
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. THE HARE INVESTMENT FUND, LP
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Chief Operating Officer
----------------------------------
Fax: Aesop Capital Partners
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
58
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ACP INVESTMENTS, LP
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Chief Operating Officer
----------------------------------
Fax: Aesop Capital Partners
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
59
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ZEKE, L.P.
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: General Partner
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
60
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. SIA PARTNERSHIP XVI
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. Sit
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. Sit
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: General Partner, SIA Partnership
----------------------------------
XVI
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
61
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. TREG HOLDINGS S.A.
(Investor)
By: By: /s/ ▇▇. ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇. ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Chief Executive Officer
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
62
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
63
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ACTIVE SITE PARTNERS, L.P.
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: General Partner
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
64
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
65
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. WHITTIER VENTURES L.L.C.
(Investor)
By: By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: President
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
66
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇. ▇. ▇▇▇▇ CO., INC. AS NOMINEE 2000-60
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇, ▇▇.
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇, ▇▇.
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Vice President
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
67
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. -----------------------------------------
(Investor)
By: By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇, M.D.
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇, M.D.
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
68
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. MERIKEN NOMINEES LTD
(Investor)
By: By: Its Director Atco Nominees Ltd.
------------------------------ -------------------------------------
By: Authorized Signatory
-------------------------------------
Name:
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
69
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇. ▇▇▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
70
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇ ▇. ▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Senior V.P. and C.F.O.
----------------------------------
Fax: c/o Mutual Risk Management Ltd.
▇▇▇-▇▇▇-▇▇▇▇ ▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇, ▇.▇. ▇▇, ▇▇▇▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
71
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. MRM LIFE LTD.
(Investor)
By: By: /s/ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Vice President
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
72
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: MRS
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
73
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇ ▇. ▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
74
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
75
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇ ▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇ ▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
76
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
77
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇ ▇▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇ ▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇ ▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Senior VP
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
78
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
79
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
80
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇ ▇. ▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
81
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
82
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
83
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇ ▇. ▇▇▇▇, ▇▇.
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇, ▇▇.
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇, ▇▇.
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
84
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC.
(Investor)
By: By: /s/ ▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
85
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
86
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇ ▇.▇. ▇▇▇▇▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇ ▇.▇. ▇▇▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇ ▇.▇. ▇▇▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
87
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇ & ▇▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Partner
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
88
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
89
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------ -------------------------------------
Name:
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
90
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
91
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
92
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC.
-----------------------------------------
(Investor)
By: By: /s/ ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title:
----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax:
93
The parties have executed this Investors' Rights Agreement as of the
date first above written.
COMPANY: INVESTORS:
DIADEXUS, INC. SMITHKLINE ▇▇▇▇▇▇▇ CORPORATION
(Investor)
By: By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
------------------------------ -------------------------------------
Name: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
-----------------------------------
Address: (print)
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Title: Secretary
-----------------------------------
Fax:
▇▇▇-▇▇▇-▇▇▇▇
FOUNDERS:
----------------------------------
SmithKline ▇▇▇▇▇▇▇ Corporation
Address:
Fax:
----------------------------------
Incyte Pharmaceuticals, Inc.
Address:
Fax: